In line with earlier studies demonstrating the beneficial effects of PARP inhibitors (or genetic PARP1 deficiency) in myocardial ischemia-reperfusion [66,67,68], both of the tested PARP inhibitors significantly improved the recovery of high-energy phosphate intermediates in the heart [69], directly confirming the well-known PARP-activation-cellular energetic failure concept. Here, PARP1 is linked to myocardial ischemia.